Daniel Knutson PhD, BS, AS
CR&D Lead Principal Scientist
Daniel Knutson joined Sterling’s Wisconsin, US facility in November 2020 as CR&D Lead Principal Scientist.
Education
-
University of Wisconsin-Milwaukee, 2020, PhD, Medicinal and Organic Chemistry
-
Rockford University, 1997, BS, Chemistry
-
Rock Valley College, 1995, AS, Chemistry
Professional Accomplishments
R1 Distinguished Dissertator Fellowship (R1DDF) in association with University of Wisconsin-Milkaukee (2019-2020)
Three Minute Thesis (3MT) finalist in association with University of Wisconsin-Milkaukee (April 2019)
Outstanding Teaching Assistant award issued by University of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry (May 2018)
Three Minute Thesis (3MT) finalist in association with University of Wisconsin-Milkaukee (April 2018)
Publications
-
Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models December 2020
ACS Pharmacology and Translational Science
-
bioRxiv
-
Reversal of Age-Related Neuronal Atrophy by α5-GABAA Receptor Positive Allosteric Modulation October 2020
Cerebral Cortex
-
Neurotherapeutics
-
Improved Scale-up Synthesis and Purification of Clinical Asthma Candidate MIDD0301 July 2020
Organic Process Research and Development
-
ACS Chemical Neuroscience
-
Pharmacology Biochemistry and Behaviour
-
European Journal of Pharmaceutical Sciences
-
The effect of pH on the structure and bio-availability of asthma drug candidate MIDD0301. February 2020
Modular Pharmaceutics
-
Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles January 2019
Molecular Neuropychiatry
-
European Journal of Pain
-
Frontiers in Pharmacology
-
Pharmaceutical Sciences and Biomedical Analysis Journal
-
Rapid-Acting Antidepressants July 2018
Current Pharmaceutical Design
-
Neuropharmacology
-
British Journal of Pharmacology
-
Journal of Medicinal Chemistry
Sterling Resources





